drugset / Trial / NCT00162071

A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

NCT00162071

Phase 2 Terminated 20 enrolled Forest Laboratories
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Timeline

Start
2005-07
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Apadenoson Small molecule

Indications